Lung Neoplasms, Venous Thromboembolism
Conditions
Keywords
lung cancer, Venous Thromboembolism
Brief summary
This is a prospective observatory clinical study, aiming to establish and validate venous thromboembolism risk model in Chinese advanced non-small cell lung cancer.
Detailed description
VTE has high incidence in lung cancer and increases the mortality. Appropriate preventive measures contribute to 50% increase of incidence. The investigators are to investigate the VTE in advanced non-small cell lung cancer and delineate the risk factors to establish a VTE risk model system helping clinicians to differentiate VTE high risk population and apply early prevention in order to reduce the incidence of VTE.
Interventions
OTHERlung cancer
If the patient is diagnosed with lung cancer in advanced stage, he/she will be followed up for VTE incidence
Sponsors
Guangdong Provincial People's Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥ 18 years at the time of screening. * Eastern Cooperative Oncology Group performance status of ≤ 2. * Written informed consent obtained from the patient. * Histologically and cytologically documented Stage 3B-4 lung cancer (according to Version 8 of the International Association for the Study of Lung Cancer Staging system). * Patients with stage 1 to 3, who undergo radical therapy with disease free survival (DFS) \>12 months. * Willingness and ability to comply with scheduled visits and other study procedures.
Exclusion criteria
* History of another primary malignancy except for malignancy treated with curative intent with known active disease ≥ 5 years before date of the informed consent. * Without signed informed consent. * Unwillingness or inability to comply with scheduled visits or other study procedures. * Previously diagnosed with VTE before signing informed consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| VTE incidence risk evaluation | 12 months | Real world VTE incidence risk evaluation in advanced lung cancer. Establish and validate VTE risk predictive model in Chinese advanced lung cancer. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| VTE incidence | 12 months | VTE incidence in advanced lung cancer. |
| VTE and overall survival | 12 months | The influence on overall survival by VTE. |
Countries
China
Contacts
Primary ContactZHEN WANG, PhD
Backup ContactXIAOLING CHEN
Outcome results
None listed